Alzheimer s Research & Therapy,
Год журнала:
2023,
Номер
15(1)
Опубликована: Окт. 2, 2023
The
arrival
of
new
disease-modifying
treatments
for
Alzheimer's
disease
(AD)
requires
the
identification
subjects
at
risk
in
a
simple,
inexpensive,
and
non-invasive
way.
With
tools
allowing
an
adequate
screening,
it
would
be
possible
to
optimize
use
these
treatments.
Plasma
markers
AD
are
very
promising,
but
is
necessary
prove
that
alterations
their
levels
related
gold
standard
such
as
cerebrospinal
fluid
or
PET
imaging.
this
research,
we
want
evaluate
performance
plasma
Aβ40,
Aβ42,
p-tau181
detect
pathological
changes
CSF
using
automated
Lumipulse
platform.Both
have
been
evaluated
group
208
cognitively
unimpaired
with
30.3%
ApoE4
carriers.
We
correlated
values
each
biomarker.
Then,
also
assessed
differences
marker
according
amyloid
status
(A
-
/
+),
(considering
+
those
A
plus
Tau
ATN
defined
by
CSF.
Finally,
ROC
curves
performed,
area
under
curve
has
measured
outcome
different
combinations
predictors.Aβ42,
ratio,
p-tau181,
p-tau181/Aβ42
ratio
significantly
between
For
markers,
were
,
groups.
Amyloid
predicts
pathology
AUC
0.89.Plasma
biomarkers
platform
show
good
diagnostic
detecting
subjects.
Alzheimer s & Dementia,
Год журнала:
2023,
Номер
20(2), С. 1284 - 1297
Опубликована: Ноя. 20, 2023
Blood
biomarkers
have
proven
useful
in
Alzheimer's
disease
(AD)
research.
However,
little
is
known
about
their
biological
variation
(BV),
which
improves
the
interpretation
of
individual-level
data.
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2023,
Номер
unknown
Опубликована: Июль 12, 2023
Phosphorylated
tau
(pTau)
is
a
specific
blood
biomarker
for
Alzheimer's
disease
(AD)
pathology,
with
pTau217
considered
to
have
the
most
utility.
However,
availability
of
tests
research
and
clinical
use
has
been
limited.
Expanding
access
this
highly
accurate
AD
crucial
wider
evaluation
implementation
tests.
To
determine
utility
novel
commercially
available
Single
molecule
array
(Simoa)
plasma
(ALZpath)
detect
pathology.
evaluate
references
ranges
abnormal
Aβ
across
three
selected
cohorts.
Three
single-centre
observational
cohorts
were
involved
in
study:
Translational
Biomarkers
Aging
Dementia
(TRIAD),
Wisconsin
Registry
Prevention
(WRAP),
Sant
Pau
Initiative
on
Neurodegeneration
(SPIN).
MRI,
Aβ-PET,
tau-PET
data
TRIAD
WRAP,
while
CSF
biomarkers
additionally
measured
subset
SPIN.
Plasma
measurements
pTau181,
(ALZpath),
pTau231,
Aβ42/40,
GFAP,
NfL,
all
Longitudinal
spanning
3
years
8
WRAP
included.
tau-PET,
(Aβ42/40
pTau
immunoassays)
(ALZpath
Simoa).
The
accuracy
detecting
amyloid
change
according
baseline
pathology
status.
study
included
786
participants
(mean
[SD]
age,
66.3
[9.7]
years;
504
females
[64.1%])
study.
High
was
observed
identifying
elevated
(AUC,
0.92-0.96;
95%CI
0.89-0.99)
0.93-0.97;
0.84-0.99)
These
accuracies
significantly
higher
than
other
combinations
comparable
biomarkers.
detection
using
binary
or
three-range
yielded
reproducible
results.
Longitudinally,
showed
an
annual
increase
only
Aβ-positive
individuals,
highest
those
tau-positivity.
ALZpath
Simoa
assay
accurately
identifies
biological
AD,
biomarkers,
cut-offs
It
detects
longitudinal
changes,
including
at
preclinical
stage,
first
widely
available,
accessible,
scalable
test
detection.
